BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Savant Capital LLC

Savant Capital LLC reduced its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 52.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,585 shares of the biotechnology company’s stock after selling 11,477 shares during the quarter. Savant Capital LLC’s holdings in BioCryst Pharmaceuticals were worth $80,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Counterweight Ventures LLC increased its stake in BioCryst Pharmaceuticals by 591.7% in the third quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company’s stock valued at $710,000 after purchasing an additional 79,884 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in BioCryst Pharmaceuticals by 40.7% in the third quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company’s stock valued at $2,274,000 after purchasing an additional 86,571 shares during the last quarter. Principal Financial Group Inc. increased its stake in BioCryst Pharmaceuticals by 1,058.1% in the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after purchasing an additional 375,890 shares during the last quarter. Rice Hall James & Associates LLC increased its stake in BioCryst Pharmaceuticals by 4.0% during the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock worth $16,444,000 after acquiring an additional 84,102 shares during the last quarter. Finally, Fisher Asset Management LLC increased its stake in BioCryst Pharmaceuticals by 16.9% during the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after acquiring an additional 481,359 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX opened at $9.39 on Thursday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $9.48. The business has a 50-day moving average of $7.94 and a 200-day moving average of $7.81. The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of -15.39 and a beta of 1.75.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Needham & Company LLC upped their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Evercore ISI upped their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. JMP Securities restated a “market outperform” rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Barclays upped their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $15.50.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.